At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARQT Arcutis Biotherapeutics Inc.
Pre-Mkt 07-09 04:20:19 EDT
28.50
+0.83
+3.00%
High28.55Low27.28Vol1.80M
Open27.37D1 Closing27.67Amplitude4.59%
Mkt Cap3.56BTradable Cap2.64BTotal Shares125.07M
T/O50.62MT/O Rate1.95%Tradable Shares92.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)
TIPRANKS  ·  00:30
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)
Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema
MT Newswires Live  ·  07-08 20:59
Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
TIPRANKS  ·  07-08 20:15
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
FDA Accepts Arcutis Snda for Zoryve Cream Use in Infants with Atopic Dermatitis
Reuters  ·  07-08 20:07
FDA Accepts Arcutis Snda for Zoryve Cream Use in Infants with Atopic Dermatitis
Arcutis Biotherapeutics - FDA Sets Pdufa Target Action Date of February 23, 2027 for Zoryve Cream 0.05% Snda
THOMSON REUTERS  ·  07-08 20:00
Arcutis Biotherapeutics - FDA Sets Pdufa Target Action Date of February 23, 2027 for Zoryve Cream 0.05% Snda
FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
THOMSON REUTERS  ·  07-08 20:00
FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
Arcutis Grants 61,000 Rsus to Nine New Hires Under 2022 Inducement Plan
Reuters  ·  07-03
Arcutis Grants 61,000 Rsus to Nine New Hires Under 2022 Inducement Plan
Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  07-03
Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Arcutis Biotherapeutics - Launches Virtual Health Platform to Expand Access to Zoryve Portfolio
THOMSON REUTERS  ·  06-30
Arcutis Biotherapeutics - Launches Virtual Health Platform to Expand Access to Zoryve Portfolio
Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use
MT Newswires Live  ·  06-30
Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
TIPRANKS  ·  06-30
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
Arcutis Says FDA Approves Zoryve Cream for Plaque Psoriasis in Children as Young as 2
Reuters  ·  06-30
Arcutis Says FDA Approves Zoryve Cream for Plaque Psoriasis in Children as Young as 2
FDA Approves Arcutis’ Zoryve® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
THOMSON REUTERS  ·  06-30
FDA Approves Arcutis’ Zoryve® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48
Reuters  ·  06-18
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48
Arcutis Stockholders Approve Proposals at 2026 Meeting
TIPRANKS  ·  06-10
Arcutis Stockholders Approve Proposals at 2026 Meeting
Arcutis Biotherapeutics shareholders elect Class III directors at annual meeting
Reuters  ·  06-10
Arcutis Biotherapeutics shareholders elect Class III directors at annual meeting
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-06
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-03
Wall Street Analysts Are Bullish on Top Healthcare Picks
Arcutis Biotherapeutics to present at Goldman Sachs Global Healthcare Conference
Reuters  ·  05-27
Arcutis Biotherapeutics to present at Goldman Sachs Global Healthcare Conference
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
TIPRANKS  ·  05-26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
No data available

Introduction

Company Name.
Arcutis Biotherapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Issue price:
--